CM Life Sciences II filed with the SEC to offer 20 million units priced at $10 each. The SPAC in the filing said it may raise an additional $75 million at the closing of a business combination under forward purchase agreements with sponsor Casdin Capital and Corvex Management.
Focusing on the life sciences sector for a potential acquisition, the SPAC is led by CEO Eli Casdin, founder of Casdin Capital, an investment firm focused on the life sciences and healthcare industry.
The SPAC said it will apply for a Nasdaq listing and has not yet slected a trading symbol. Read more.
